Zoetis Inc.

NYSE:ZTS

Sector

🛒 Consumer Staples

Industries

🐶 Pet Food

🧬 Biotechnology

🍔 Meat

💊 Pharmaceuticals

Location

United States

Market Cap

USD 69.53 B

Share Price

USD 156.17

Avg Daily Volume

2,897,195

Change (1 day)

0.24%

Change (1 year)

-11.50%

Change (YTD)

-4.15%

Zoetis Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2025: USD 20.56

Zoetis Inc. Revenue Per Share is USD 20.56 for the Trailing 12 Months (TTM) ending March 31, 2025, a 8.24% change year over year. Revenue per share indicates revenue generated per share; higher ratios suggest stronger performance and value.

Zoetis Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2024 was USD 19.00, a 9.53% change year over year.
Zoetis Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2023 was USD 17.34, a 4.07% change year over year.
Zoetis Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2022 was USD 16.66, a 12.99% change year over year.
Zoetis Inc. Revenue Per Share for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 14.75, a 11.01% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Revenue Per Share	Free Cash Flow Per Share	Dividend Per Share	Debt to Equity Ratio

NYSE: ZTS

Zoetis Inc.

CEO	Ms. Kristin C. Peck
IPO Date	Feb. 1, 2013
Location	United States
Headquarters	10 Sylvan Way
Employees	13,800
Sector	🛒 Consumer Staples
Industries Pet Food 🧬 Biotechnology 🍔 Meat 💊 Pharmaceuticals

Description

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.